Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma

Conditions:   Pediatric Solid Tumor;   Pediatric Lymphoma;   Pediatric Brain Tumor Intervention:   Drug: CLR 131 Sponsor:   Cellectar Biosciences, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials